Ben Cravatt, Founder
Ben Cravatt, Ph.D.
Professor, Scripps Research

Benjamin F. Cravatt, Ph.D., is a the Gilula Chair of Chemical Biology and Professor in the Department of Chemistry at Scripps Research. His research group develops and applies chemical proteomic technologies for protein and drug discovery on a global scale and has particular interest in studying biochemical pathways in the nervous system and cancer.  Dr. Cravatt is a co-founder of Belharra Therapeutics, Activx Biosciences (acquired by Kyorin Pharmaceuticals), Abide Therapeutics (acquired by Lundbeck Pharmaceuticals), and Vividion Therapeutics. His honors include a Searle Scholar Award, the Eli Lilly Award in Biological Chemistry, a Cope Scholar Award, the ASBMB Merck Award, the Royal Society of Chemistry Jeremy Knowles Award, The Wolf Prize, and memberships in the National Academy of Sciences, National Academy of Medicine, and American Academy of Arts and Sciences.

Ben obtained his undergraduate education at Stanford University, receiving a B.S. in the Biological Sciences and a B.A. in History. He then received a Ph.D. from Scripps Research in 1997, and joined the faculty at Scripps in 1997.

“You have to be different. Belharra has the potential to be truly transformative. This company will excel because of how different it is in its approach.”